NEJM Retracts Avacopan Vasculitis Study

• by Kathryn Wighton

• July 1, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

• by Kathryn Wighton

• August 28, 2026

• 2 min

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

• by Kathryn Wighton

• September 1, 2026

• 2 min

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

• by Andrea Surnit

• August 31, 2026

• 4 min